Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tafasitamab - Incyte Corporation/MorphoSys

Drug Profile

Tafasitamab - Incyte Corporation/MorphoSys

Alternative Names: anti-CD19 MAb XmAb5574; anti-CD19 MoAb XmAb5574; INCMOR0208; Minjuvi; Monjuvi; MOR 208; MOR-00208; Tafasitamab-cxix; XENP-5574; XmAb-5574

Latest Information Update: 09 Nov 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Xencor
  • Developer Incyte Corporation; MorphoSys; University Medical Center of the Johannes Gutenberg University Mainz; Xencor
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Diffuse large B cell lymphoma
  • Phase III Follicular lymphoma; Marginal zone B-cell lymphoma
  • Phase II B-cell lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 02 Nov 2021 Incyte Corporation plans phase II coreMIND trial for Chronic lymphocytic leukaemia (Second-line therapy or greater) in USA
  • 21 Oct 2021 Tafasitamab licensed to Specialised Therapeutics Asia in Australia, New Zealand and Singapore
  • 26 Aug 2021 Registered for Diffuse large B cell lymphoma (Combination therapy, Second-line therapy or greater) in European Union, Norway, Iceland, Liechtenstein (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top